Aprea Therapeutics, Inc.

APRE

NASDAQ

Healthcare

Biotechnology

Boston, MA, US8 employeesatrinpharma.com

$0.71

+0.00(0.34%)

Mkt Cap $5M

$0.59

$2.08

52-Week Range

At a Glance

AI-generated

Aprea Therapeutics, Inc.

8-K

Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds intended for general corporate purposes and research and development expenses.

$5M

Market Cap

$241.4K

Revenue

-$11M

Net Income

Employees8

Fundamentals

How The Business Makes Money

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Delisting

Jan 22, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 23, 2026, Aprea Therapeutics, Inc. (the “Compa

Financial Results

Mar 15, 2026

, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac

Regulation FD

Mar 31, 2026

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or o

Material Agreement+4 More

Mar 29, 2026

Entry Into a Material Definitive Agreement.** On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “

Other Event

Feb 17, 2026

Other Events. On February 18, 2026, Aprea Therapeutics, Inc. issued a press release announcing the second unconfirmed partial response (uPR) observed in a patie

Peer Companies

Company	Price	Change	Market Cap	P/E
GLTOGalecto, Inc.	$25.23	+0.60%	$40M	-0.2
RNAZTransCode Therapeutics, I...	$8.68	-0.07%	$8M	-0.3
KPRXKiora Pharmaceuticals, In...	$1.96	+0.51%	$8M	-1.0
APVOAptevo Therapeutics Inc.	$4.13	-0.97%	$7M	-0.0
BCDABioCardia, Inc.	$1.19	+2.59%	$7M	-0.9
INABIN8bio, Inc.	$1.46	+3.93%	$7M	-0.4
ACXPAcurx Pharmaceuticals, In...	$3.72	-4.37%	$6M	-0.9
CELZCreative Medical Technolo...	$2.05	+3.02%	$5M	-0.7

Analyst View

Company Profile

CIK0001781983

ISINUS03836J2015

CUSIP03836J102

Phone617-463-9385

Address535 Boylston St., Boston, MA, 02116, US

SEC EDGAR